This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Etsy Files IPO; AbbVie Pharma Deal and Costco Profits Higher

3/05/15 7:31 AM EST
Girl favorite shopping destination Etsy has filed for an IPO of up to $100 million while Chicago-based AbbVie is set to buy another company called Pharmacyclics and Costco profits were up 29%, helped by a hefty tax boost. The online destination for homemade crafts, arts and jewelry, Etsy started in 2005, aims to raise 100 million with its move to start trade as a public company. Most of its revenue comes from sellers who pay a fee to list items for sale. It will list on the Nasdaq under the ticker symbol ETSY. Abbvie is boosting its cancer treatment pipeline with its 21 billion dollar purchase of Pharmacyclics. Until recently, Abbie's blockbuster drug was Humira, which treats rheumatoid arthritis, and was a big revenue driver. But with a forecasted sales decline a few years out, Abbvie is working to boost its pipeline with this deal. Costco saw a boost in its latest earnings report card thanks to a tax boost. Numbers were better than-expected thanks to a tax benefit related to its special cash dividend last month. Net income rose to a better than expected $1.35 per share, up from $1.05 in the same period a year ago.
Stocks in this video: COSTPCYCABBV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs